Weight Support Programs
US$ 23.28
surmount study tirzepatide SURMOUNT-1 Trial SURPASS to SURMOUNT: The Tirzepatide
Description
not for glycemic control) * Increase to 0.5 mg once weekly * If needed after at least 4 weeks: increase to 1 mg once weekly * May increase to 2 mg once weekly if additional glycemic control is required Administration * Inject subcutaneously into the abdomen, thigh, or upper arm
Semazic Injection 0.5 mg/0.375 ml ( . /. ) is a product of Square Pharmaceuticals PLC
:
Undergoing surgery while on semaglutide requires careful planning with your surgical team
Fixed Dose Selection: The dial mechanism is mechanically engineered to click and lock perfectly at the 0.5 mg mark for each weekly injection
